ライフサイエンスコーパス: unstable angina

1 y revascularization, and hospitalization for unstable angina).

2 -segment elevation myocardial infarction; 6% unstable angina).

3 nts (composite of CAD death, nonfatal MI, or unstable angina).

4 he trial of death, myocardial infarction, or unstable angina.

5 t (within 3 months) myocardial infarction or unstable angina.

6 vation myocardial infarction, and 23.6% with unstable angina.

7 events, including 141 MIs and 84 episodes of unstable angina.

8 -STEMI (NSTEMI), and 19 777 (40% women) with unstable angina.

9 ns exist regarding the use of angiography in unstable angina.

10 non-ST-elevation myocardial infarction, and unstable angina.

11 cardial infarction and rehospitalization for unstable angina.

12 ups and do not include subgroup analysis for unstable angina.

13 ndromes, including myocardial infarction and unstable angina.

14 her vascular events, and hospitalization for unstable angina.

15 8 months after receiving 2 Cypher stents for unstable angina.

16 hemic stroke, transient ischemic attack, and unstable angina.

17 ome, including patients with enzyme-negative unstable angina.

18 ath, myocardial infarction, or admission for unstable angina.

19 onset, while in 52% it was class II to IV or unstable angina.

20 iagnosis in 1 man was downgraded from AMI to unstable angina.

21 , and stroke, as well as hospitalization for unstable angina.

22 non-fatal stroke) or hospital admission for unstable angina.

23 ion, nonfatal stroke, or hospitalization for unstable angina.

24 the primary outcome plus hospitalization for unstable angina.

25 l infarction, stroke, or hospitalization for unstable angina.

26 classified as myocardial infarction (MI) and unstable angina.

27 rwent PCI for acute myocardial infarction or unstable angina.

28 ients), myocardial infarction (17 patients), unstable angina (10 patients), or stroke (3 patients).

29 reatments for acute myocardial infarction or unstable angina (10%), treatments for heart failure (9%)

30 ), and refractory post-myocardial infarction unstable angina (10.0%).

31 rdial infarction, 105,708 [21.1%]; high-risk unstable angina, 146,464 [29.3%]), and 144,737 (28.9%) f

32 ial infarction, 13.1% (95% CI, 1.1-23.7) for unstable angina, 16.4% (95% CI, 15.1-17.7) for heart fai

33 non-ST-elevation myocardial infarction, 218 unstable angina, 163 sudden cardiac death); 188 (9%) per

34 e readmitted with chest pain consistent with unstable angina 173+/-39 days after CABG.

35 her in the MI group (7.5%) compared with the unstable angina (2.7%) and non-ACS (2.6%) groups (P < .0

36 mized 360 patients presenting with stable or unstable angina (28% of patients) and negative Troponin

37 and RITA-3 (Randomized Intervention Trial of Unstable Angina 3) non-ST-elevation acute coronary syndr

38 al infarction, 83.8% [95% CI, 83.3-84.4] for unstable angina, 30.5% [95% CI, 29.3-31.6] for heart fai

39 in both groups were males who presented with unstable angina; 36% were diabetic.

40 e rupture occurred not only in patients with unstable angina (46%) or myocardial infarction (MI, 33%)

41 0.1+/-15.4% versus 45.4+/-23.3%; P<0.01) and unstable angina (67.4+/-12.9% versus 45.4+/-23.3%; P>0.0

42 Stable and unstable angina accounted for most (43%) of the cardiova

43 infarction, coronary revascularisation, and unstable angina (active treatment HR 0.89, 95% CI 0.79-0

44 admitted with acute myocardial infarction or unstable angina (acute coronary syndromes) were randomiz

45 mic stroke, myocardial infarction, new-onset unstable angina, acute coronary interventions, and vascu

46 acute coronary syndromes (ACS) present with unstable angina, acute myocardial infarction, and sudden

47 e for coronary thrombosis, the main cause of unstable angina, acute myocardial infarction, and sudden

48 over the initial year of treatment and more unstable angina admissions (hazard ratio=2.8 [1.1-7.5]).

49 evascularisation alone (0.84, 0.75-0.94) and unstable angina alone (0.81, 0.67-0.97) during full foll

50 placebo, on acute coronary syndromes (MI and unstable angina) among IRIS participants.

51 ith men, women were older and more often had unstable angina and congestive heart failure, lower phys

52 Patients with unstable angina and electrocardiographic changes or non-

53 Trial participants had typical symptoms of unstable angina and frequently had a positive electrocar

54 Likewise, clinical scenarios with unstable angina and intermediate- or high-risk features

55 ased risk of acute ischemic coronary events (unstable angina and myocardial infarction) equal to 4.5%

56 n CRP and SAA were observed in patients with unstable angina and non-Q-wave myocardial infarction, wi

57 2220 patients hospitalized with unstable angina and non-ST-segment elevation MI who were

58 e ischemic outcomes in elderly patients with unstable angina and non-ST-segment elevation MI.

59 initiative included high-risk patients with unstable angina and non-ST-segment elevation myocardial

60 ed risk of adverse outcomes in patients with unstable angina and non-ST-segment elevation myocardial

61 t elevation acute coronary syndromes include unstable angina and non-ST-segment elevation myocardial

62 ctrum of clinical presentations ranging from unstable angina and non-ST-segment elevation myocardial

63 h poorer clinical outcomes in the setting of unstable angina and non-STEMI and after percutaneous cor

64 s significant reduction in revascularization/unstable angina and nonsignificant reductions in other c

65 ath and myocardial infarction) or secondary (unstable angina and revascularization) events.

66 ent depression in patients with recent MI or unstable angina and without other life-threatening medic

67 ry artery disease, 2806 hospitalizations for unstable angina, and 1029 fatal or nonfatal strokes occu

68 Fifty-nine percent presented with new unstable angina, and 9.3% presented with nonfatal myocar

69 arbepoetin, with higher incidences of death, unstable angina, and arrhythmia with peginesatide.

70 MACE endpoint also included all-cause death, unstable angina, and coronary revascularization.

71 patients with recent myocardial infarction, unstable angina, and depressed ventricular function.

72 cularization procedures, hospitalization for unstable angina, and diagnosis of new ischemic heart dis

73 hypertension, diabetes, renal insufficiency, unstable angina, and heart failure, but less smoking.

74 on, non-fatal stroke, hospital admission for unstable angina, and hospital admission for heart failur

75 atal stroke, urgent revascularisation due to unstable angina, and hospital admission for heart failur

76 MLD, longer stent length, diabetes mellitus, unstable angina, and hypertension were independent predi

77 chemic attack, intracerebral hemorrhage, and unstable angina, and inverse (0.69) for subarachnoid hem

78 hophysiology of acute myocardial infarction, unstable angina, and ischemic stroke.

79 resenting clinical syndromes (stable angina, unstable angina, and MI).

80 dial infarction, coronary revascularisation, unstable angina, and new angina during active treatment

81 -ST-segment-elevation myocardial infarction, unstable angina, and non-acute coronary syndrome) in The

82 cardial infarction, acute coronary syndrome, unstable angina, and stroke) is unclear.

83 ther events, including recurrent infarction, unstable angina, and stroke.

84 le, diabetic, not currently smoking, to have unstable angina, and to have a prior PCI.

85 -segment elevation myocardial infarction and unstable angina, and venous thromboembolism prophylaxis.

86 xamined: (1) myocardial infarction (MI); (2) unstable angina; and (3) revascularization not associate

87 stive failure, hypertension, prior CABG, and unstable angina; and had higher body mass index and lowe

88 cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke).

89 rction [MI], congestive heart failure [CHF], unstable angina, arrhythmia, symptomatic hypotension, or

90 nfarction, stroke, admission to hospital for unstable angina, arterial revascularisation, or cardiova

91 al infarction or stroke, hospitalisation for unstable angina, arterial revascularisation, or cardiova

92 infarction, non-fatal stroke, admission for unstable angina, arterial revascularisation, or cardiova

93 al infarction or stroke, hospitalization for unstable angina, arterial revascularization, or cardiova

94 ardial infarction, stroke, hospital stay for unstable angina, arterial revascularization, or confirme

95 scular disease (CVD) (myocardial infarction, unstable angina, arterial revascularization, stroke, or

96 s with recent acute myocardial infarction or unstable angina as a prognostic indicator for eventual c

97 Patients with unstable angina benefit from an invasive management path

98 on Therapy) were used to report rates of MI, unstable angina, cardiac arrest, and cardiac death and t

99 Annual rates of a composite of MI, unstable angina, cardiac arrest, and cardiac death were

100 ained ACS, defined as myocardial infarction, unstable angina, cardiac arrest, or death due to ischemi

101 s included acute myocardial infarction (MI), unstable angina, cardiac catheterization, percutaneous t

102 MACE defined as acute myocardial infarction, unstable angina, cardiogenic shock, ventricular arrhythm

103 dial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart fa

104 ents including death, myocardial infarction, unstable angina, coronary revascularization, stroke, tra

105 (fatal and nonfatal myocardial infarctions, unstable angina, deaths from coronary heart disease, fat

106 Patients with myocardial infarction and unstable angina demonstrate increased total binding of p

107 ercutaneous coronary intervention [PCI], and unstable angina) derived from previous studies.

108 Patients with a stable or unstable angina diagnosis or documented silent ischemia

109 o be male, younger, and with higher rates of unstable angina, emergency operation, recent or transmur

110 The adjusted odds of MACE for the unstable angina group were similar to those for the non-

111 s severe types of ACS at presentation (e.g., unstable angina > non-ST-segment elevation MI > ST-segme

112 002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.7

113 Reductions in risk of hospitalization for unstable angina (hazard ratio, 0.55; 95% confidence inte

114 non-fatal stroke, admission to hospital for unstable angina, heart failure, and all-cause mortality.

115 , myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular

116 condary analysis, additional events included unstable angina, heart failure, or stroke at five years.

117 cular disease events (myocardial infarction, unstable angina, heart failure, or stroke) in relation t

118 or non-fatal stroke, hospital admission for unstable angina, hospital admission for heart failure, d

119 or non-fatal stroke, hospital admission for unstable angina, hospital admission for heart failure, o

120 s all-cause death, myocardial infarction, or unstable angina hospitalization over a median follow-up

121 rtality, nonfatal myocardial infarction, and unstable angina hospitalization was similar and fair for

122 omposite of death, myocardial infarction, or unstable angina hospitalization.

123 d point was death, myocardial infarction, or unstable angina hospitalizations over a median follow-up

124 d toward an increase in hospitalizations for unstable angina (HR, 1.37; 95% CI, 0.99 to 1.91; P = 0.0

125 ndication was MI in 32.8% of the procedures, unstable angina in 33.8%, and non-ACS in 33.4%.

126 nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hyperte

127 all patients treated with PCI for stable or unstable angina in small native coronary vessels (refere

128 ss the effect of angiography on mortality in unstable angina, incorporating the results of additional

129 rdiac death (3), myocardial infarction (12), unstable angina/ischemic ventricular fibrillation (2), s

130 tion, stroke, coronary revascularisation, or unstable angina; key secondary endpoint was the composit

131 all-cause mortality, myocardial infarction, unstable angina leading to hospitalization, and revascul

132 te (within 6 months), age, gender, stable or unstable angina, lesion location, and additional treatme

133 female gender, body mass index <25 kg/m(2), unstable angina, moderate or poor ejection fraction, and

134 I (adjusted OR, 0.77; 95% CI, 0.63-0.95) and unstable angina, mortality was lower among women (adjust

135 Acute coronary syndromes--unstable angina, myocardial infarction, and sudden cardi

136 evels), major adverse cardiovascular events (unstable angina, myocardial infarction, death), and safe

137 /=65 years of age who were hospitalized with unstable angina, myocardial infarction, heart failure, i

138 Emergently admitted patients with unstable angina (n = 33 901) who did or did not receive

139 et, with acute coronary syndromes defined as unstable angina (n=12) and acute myocardial infarction (

140 sion [n = 7], myocardial infarction [n = 5], unstable angina [n = 3], pericarditis [n = 2], arrhythmi

141 mia (ie, acute myocardial infarction [MI] or unstable angina; n = 329), there were no differences in

142 gible patients were older than 18 years with unstable angina, non-ST segment elevation myocardial inf

143 ndrome encompasses three clinical diagnoses: unstable angina, non-ST-segment elevation myocardial inf

144 in comparison with UFH in the management of unstable angina/ non-ST-segment elevation myocardial inf

145 clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infa

146 Unstable angina/non-ST-elevation myocardial infarction (

147 asymptomatic/mild angina, stable angina, and unstable angina/non-ST-elevation myocardial infarction b

148 -elevation myocardial infarction, 35527 with unstable angina/non-ST-elevation myocardial infarction,

149 rican College of Cardiology for treatment of unstable angina/non-ST-elevation myocardial infarction.

150 Diagnosing unstable angina/non-ST-segment elevation myocardial infa

151 al presentation, diagnosis, and treatment of unstable angina/non-ST-segment elevation myocardial infa

152 ce of these agents in treating patients with unstable angina/non-ST-segment elevation myocardial infa

153 n scintigraphy (SPS) in patients with recent unstable angina/non-ST-segment elevation myocardial infa

154 n (GP) IIb/IIIa inhibitors are beneficial in unstable angina/non-ST-segment elevation myocardial infa

155 s and DAPT in the postdischarge treatment of unstable angina/non-ST-segment-elevation myocardial infa

156 s among specific PPI agents in patients with unstable angina/non-ST-segment-elevation myocardial infa

157 yocardial infarction [STEMI] and 15,459 with unstable angina/non-STEMI [UA/NSTEMI]), of whom 10 613 (

158 enoxaparin in improving clinical outcomes in unstable angina/NSTEMI patients has led to investigation

159 ry revascularization, or hospitalization for unstable angina, occurred in 446 of the participants who

160 blind randomised trial in 1439 patients with unstable angina or acute myocardial infarction.

161 ypertension and 28 cardiovascular events (17 unstable angina or arrhythmia, 3 nonfatal stroke, 3 hear

162 ypertension and 31 cardiovascular events (11 unstable angina or arrhythmia, 8 nonfatal myocardial inf

163 se, coronary arterial revascularization, and unstable angina or congestive heart failure requiring ho

164 rdiac death, myocardial infarction (MI), and unstable angina or congestive heart failure warranting h

165 Eligible patients had stable or unstable angina or documented silent ischaemia, and a ma

166 rs) and most patients presenting either with unstable angina or for percutaneous coronary interventio

167 reference group and had the highest risk of unstable angina or myocardial infarction (HR, 5.84 [3.43

168 (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an

169 sified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segm

170 Among patients with unstable angina or myocardial infarction without ST-segm

171 n=375,886) or acute coronary syndromes (ACS; unstable angina or myocardial infarction, n=450,329) at

172 nt ischaemic events in patients admitted for unstable angina or myocardial infarction.

173 with either stable (n=226) or unstable CAD (unstable angina or myocardial infarction; n=156).

174 In the MIRACL trial, 3,086 patients with unstable angina or non-Q-wave myocardial infarction were

175 Subjects with unstable angina or non-Q-wave myocardial infarction were

176 d, placebo-controlled trial of patients with unstable angina or non-Q-wave myocardial infarction.

177 Unstable angina or non-ST-elevation myocardial infarctio

178 ND PATIENTS: Patients with medically managed unstable angina or non-ST-segment elevation myocardial i

179 nts with multivessel disease presenting with unstable angina or non-ST-segment elevation myocardial i

180 -eluting stent implantation in patients with unstable angina or non-ST-segment elevation myocardial i

181 rction (TIMI) 18 trial, patients with either unstable angina or non-ST-segment elevation myocardial i

182 baseline and in patients with stable angina, unstable angina, or a history of myocardial infarction.

183 , myocardial infarction, hospitalization for unstable angina, or any coronary revascularization).

184 adverse events of congestive heart failure, unstable angina, or arrhythmia--with the use of pooled d

185 atal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.

186 l infarction, stroke, hospital admission for unstable angina, or coronary revascularisation.

187 dial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

188 dial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

189 l infarction, stroke, hospital admission for unstable angina, or coronary revascularization.

190 erial revascularization, hospitalization for unstable angina, or death from cardiovascular causes).

191 erial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.

192 and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure

193 , myocardial infarction, hospitalization for unstable angina, or major procedural complication.

194 onstituting non-ST-segment elevation AMI and unstable angina, or stable angina pectoris (SAP).

195 )-myocardial infarction, hospitalization for unstable angina, or urgent/emergency coronary revascular

196 olecule 1 (P<0.001), and previous history of unstable angina (P=0.01) were independent predictors of

197 -term mortality than patients diagnosed with unstable angina (P=0.05).

198 tive protein levels were reduced (P=0.03) in unstable angina patients receiving amoxicillin, and fibr

199 ta from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

200 ta from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

201 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

202 lled in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

203 ting in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

204 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

205 08 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

206 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

207 lled in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

208 on, and the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

209 he CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

210 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

211 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

212 00 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

213 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

214 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

215 ting in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

216 ts from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

217 ears in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

218 We linked Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

219 The crude all-cause 1-year mortality for unstable angina patients with H-FABP <5.8 microg/l was 2

220 Patients with MI and unstable angina pectoris had higher VEGF levels compared

221 ents with acute coronary syndrome (82 MI, 44 unstable angina pectoris).

222 ligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial

223 ents presenting with stable angina pectoris, unstable angina pectoris,and ST-segment elevation myocar

224 ed in patients with myocardial infarction or unstable angina pectoris.

225 oronary artery disease, history of stable or unstable angina, previous multi-vessel percutaneous coro

226 hypertension; diabetes mellitus; nonsmokers; unstable angina; previous coronary artery bypass graftin

227 ts (acute myocardial infarction, arrhythmia, unstable angina, pulmonary embolism) and little or no as

228 , neurological disease, active endocarditis, unstable angina, recent myocardial infarction, and pulmo

229 e PURSUIT (Platelet Glycoprotein IIB/IIIA In Unstable Angina: Receptor Suppression Using Integrilin T

230 USTO)-IIb, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin T

231 In patients in whom unstable angina remains a concern or there is a desire t

232 , death, reinfarction, rehospitalization for unstable angina, repeat coronary revascularization (targ

233 rate of all-cause mortality, nonfatal MI, or unstable angina requiring hospitalization at 4 years.

234 and either an acute myocardial infarction or unstable angina requiring hospitalization within the pre

235 l myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization) in multivaria

236 ction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower wit

237 site of all-cause mortality, nonfatal MI, or unstable angina requiring hospitalization; the secondary

238 cular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re

239 ath due to any cause, myocardial infarction, unstable angina requiring rehospitalization, revasculari

240 ll causes, myocardial infarction, documented unstable angina requiring rehospitalization, revasculari

241 any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revasculari

242 ary end point (death, myocardial infarction, unstable angina requiring rehospitalization, stroke, or

243 ch additionally included hospitalisation for unstable angina requiring unplanned revascularisation) a

244 rction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or c

245 osites of death, myocardial infarction (MI), unstable angina, revascularization >30 days, and stroke

246 Secondary outcomes (unstable angina, revascularization procedures) were abst

247 end point was death, myocardial infarction, unstable angina, revascularization, or stroke (mean foll

248 The third Randomized Intervention Trial of unstable Angina (RITA-3) evaluated early IS (n = 895) ve

249 , the third Randomized Intervention Trial of unstable Angina (RITA-3) recently reported a halving of

250 ere was a reduction in rehospitalization for unstable angina (RR = 0.69, 95% CI 0.65 to 0.74, p < 0.0

251 art failure (CHF) within 4 weeks before CEA; unstable angina; steroid-dependent chronic obstructive p

252 h, acute MI, new congestive heart failure or unstable angina, stroke, and significant ventricular arr

253 dial infarction, coronary revascularization, unstable angina, stroke, or congestive heart failure.

254 subsequent vascular events in patients with unstable angina, the cost-effectiveness of this combinat

255 ugh early invasive therapy reduces recurrent unstable angina, the magnitude of benefit on other impor

256 The diagnosis in 2 women was upgraded from unstable angina to AMI, and the diagnosis in 1 man was d

257 155 to 271 mg/dl 3 to 36 months after MI or unstable angina to placebo or pravastatin 40 mg per day.

258 ere bleeding according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and T

259 l alone versus aspirin alone, Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) in fa

260 The incidence of Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) major

261 Patients (n=5059) from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) rando

262 r ACS was demonstrated in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial

263 lopidogrel and placebo (CURE [Clopidogrel in Unstable Angina to Prevent Recurrent Events], CREDO [Clo

264 In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CU

265 entional Treatment Strategy in Patients with Unstable Angina) trials for a collaborative meta-analysi

266 ) (n = 20), stable angina (SA) (n = 20), and unstable angina (UA) (n = 10).

267 an acute myocardial infarction (MI) (n = 8), unstable angina (UA) (n = 15), stable coronary artery di

268 routine invasive approach for patients with unstable angina (UA) and non-ST-segment elevation myocar

269 ne early use of clopidogrel in patients with unstable angina (UA) and non-ST-segment elevation myocar

270 for unplanned coronary revascularization and unstable angina (UA) are common.

271 creased CHD death/myocardial infarction (MI)/unstable angina (UA) event rate in carriers of the GP1BA

272 real-world, medically managed patients with unstable angina (UA) or non-ST-segment elevation myocard

273 ent elevation myocardial infarction (NSTEMI)/unstable angina (UA) who were managed medically without

274 oronary intervention for stable angina (SA), unstable angina (UA), or acute myocardial infarction (AM

275 myocardial infarction (STEMI), non-STEMI, or unstable angina (UA).

276 ischemia in postmenopausal (PMP) women with unstable angina (UA).

277 ere significantly increased in patients with unstable angina (UA).

278 re 2 trials of an early invasive strategy in unstable angina (UA)/non-ST-elevation myocardial infarct

279 ) bleeding among patients with elective PCI, unstable angina (UA)/non-ST-segment elevation myocardial

280 nder and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial

281 Risk stratification in unstable angina (UA)/non-ST-segment elevation myocardial

282 aphic and clinical outcomes in patients with unstable angina (UA)/non-ST-segment elevation myocardial

283 ] death, myocardial infarction [MI], stroke, unstable angina [UA] leading to hospitalization, coronar

284 infarction; three patients with progressive unstable angina underwent diagnostic coronary angiograph

285 g angiography within 2 months of their index unstable angina versus 0.097 (CI, 0.090 to 0.105) for th

286 n-ST-segment-elevation myocardial infarction/unstable angina versus elective) and PCI volume.

287 ard ratio, 4.06; 95% CI, 1.84-8.94; P<0.001; unstable angina versus non-ACS: adjusted hazard ratio, 1

288 iovascular event plus hospital admission for unstable angina was greater than 1.3, a dedicated study

289 (n=8) specimens from patients with stable or unstable angina were classified as complicated or uncomp

290 atal events; and 1.21 (1.04-1.41) if TIA and unstable angina were further excluded.

291 ndomized trial, 2008 patients with stable or unstable angina were randomly assigned in a 2:1 ratio to

292 d recurrent ischemic events (recurrent MI or unstable angina) were identified through Olmsted County,

293 MRS was primarily due to hospitalization for unstable angina, which is associated with repeat cathete

294 diabetic patients with medically refractory unstable angina who are at high risk for CABG.

295 cardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hosp

296 -segment elevation myocardial infarction, or unstable angina with high-risk features) or nonacute ind

297 spitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes occurred between F

298 tion myocardial infarction within 7 days, or unstable angina within 48 h of randomization.

299 infarction or who had been hospitalized for unstable angina within the previous 180 days to receive

300 ninvasive stress results (n = 1906; 57%) and unstable angina without high-risk features (n = 902; 27%